Regulation of Vascular Graft Healing by Induction of Tissue Incorporation

  • Howard P. Greisler


The phrase vascular graft healing implies the encapsulation of prosthetic material by host tissue. Healing occurs at the external surface, interstitium, and luminal surface of the graft, and results in the presence of living cells and acellular stroma in and around the prostheses. Investigators have characterized the end results of this process in response to numerous prosthetic materials over the course of four decades. Until recently, the guiding premise has been that biomaterials should be biologically inert. No truly inert material has yet been developed. Clinical results using currently available biomaterials have been disappointing, especially in the arena of small diameter vascular grafts. An alternative philosophical approach, which has been the topic of recent investigation, involves optimization of the tissue—biomaterial interaction to enlist the natural healing process to cooperate in the formation of the ideal vascular conduit.


Vascular Graft Tissue Ingrowth Vascular Prosthesis ePTFE Graft Capsule Thickness 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Vromen L. What time does the next protein arrive? Trans Soc Biomater 1986; 9: 59.Google Scholar
  2. 2.
    Vromen L. Methods of investigating protein interaction on artificial and natural surfaces. Ann Nyacad Sci 1987; 516: 300–305.CrossRefGoogle Scholar
  3. 3.
    Roohk HV, Pick J, Hill R, Hung E, and Bartlett RH. Kinetics of fibrinogen and platelet adherence to biomaterials. Trans ASAIO 1976; 22: 1–7.Google Scholar
  4. 4.
    Ito RK, Rosenblatt MS, Contreras MA, Brophy CM, and LoGerfo FW. Monitoring platelet interactions with prosthetic graft implants in a canine model. Trans ASAIO 1990; 36: M175 — M178.Google Scholar
  5. 5.
    McCollum CN, Kester RC, Rajah SM, Learoyd P, and Pepper M. Arterial graft maturation: the duration of thrombotic activity in Dacron aortobifemoral grafts measured by platelet and fibrinogen kinetics. BrJSurg 1981; 68: 61–64.Google Scholar
  6. 6.
    Goldman M, Norcott HC, Hawker RJ, Drolc Z, and McCollum CN. Platelet accumulation on mature Dacron grafts in man. Br J Surg 1982; 69 (Suppl): S38 — S40.CrossRefGoogle Scholar
  7. 7.
    Stratton JR, Thiele BL, and Ritchie JL. Platelet deposition on Dacron aortic bifurcation grafts in man: quantitation with indium-111 platelet imaging. Circulation 1982; 66: 1287–1293.CrossRefGoogle Scholar
  8. 8.
    Stratton JR, Thiele BL, and Ritchie JL. Natural history of platelet deposition on Dacron aortic bifurcation grafts in the first year after implantation. Am J Cardiol 1983; 52: 371–374.CrossRefGoogle Scholar
  9. 9.
    Chenoweth DE. Complement activation in extracorporeal circuits. Ann NYAcad Sci 1987; 516: 306–313.CrossRefGoogle Scholar
  10. 10.
    Shepard AD, Gelfand JA, Callow AD, and O’Donnell TF Jr. Complement activation by synthetic vascular prostheses. J Vasc Surg 1984; 1: 829–838.Google Scholar
  11. 11.
    Lackle JM and DeBono D. Interactions of neutrophil granulocytes and endothelium in vitro. Microvasc Res 1977; 13: 107–112.CrossRefGoogle Scholar
  12. 12.
    Tonnesin MG, Smedly LA, and Henson PM. Neutrophil-endothelial cell interactions: modulation of neutrophil adhesiveness induced by complement fragments C5a and C5a des arg and formymethionyl-leucyl-phenylalanine in vitro. J Clin Invest 1984; 74: 1581–1592.CrossRefGoogle Scholar
  13. 13.
    Bevilacqua MP, Pober JS, Wheeler ME, Cotran RS, and Gimbrone JA Jr. Interleukin-1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes and related leukocyte cell lines. J Clin Invest 1985; 76: 2003–2011.CrossRefGoogle Scholar
  14. 14.
    Gamble JR, Harlan JM, Lebanoff SJ, and Vadas MA. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci USA 1985; 82: 8667–8671.CrossRefGoogle Scholar
  15. 15.
    Greisler HP. Interactions at the blood/material interface. Ann Vasc Surg 1990; 4: 98–103.CrossRefGoogle Scholar
  16. 16.
    Deuel TF, Senior RM, Huang JS, and Griffin GL. Chemotaxis of monocytes and neutrophils to platlet-derived growth factor. J Clin Invest 1982; 69: 1046–1049.CrossRefGoogle Scholar
  17. 17.
    Fox PL and DiCorleto PE. Regulation of production of a platelet-derived growth factor-like protein by cultured bovine aortic endothelial cells. J Cell Physiol 1984; 121: 298–308.CrossRefGoogle Scholar
  18. 18.
    Clowes AW, Kirkman TR, and Clowes MM. Mechanisms of arterial graft failure. II. Chronic endothelial and smooth muscle cell proliferation in healing polytetrafluoroethylene prostheses. J Vasc Surg 1986; 3: 877–884.Google Scholar
  19. 19.
    DiCorleto PE and De La Motte CA. Characterization of the adhesion of the human monocytic cell line U-937 to cultured endothelial cells. J Clin Invest 1985; 75: 1153–1161.CrossRefGoogle Scholar
  20. 20.
    Margiotta MS, Robertson FS, and Greco RS. The adherence of endothelial cells to Dacron induces the expression of the intercellular adhesion molecule (ICAM-1). Ann Surg 1992; 216: 600–604.CrossRefGoogle Scholar
  21. Ford-Hutchinson AW, Bray MA, Doig MV, Shipley ME, and Smith MJ. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature (Lond) 1980; 286: 264–265.Google Scholar
  22. 22.
    Deuel TF, Senior RM, Chang D, Griffin GL, Heinrikson RL, and Kaiser ET. Platelet factor 4 is chemotactic for neutrophils and monocytes. Proc Natl Acad Sci USA 1981; 78: 4584–4587.CrossRefGoogle Scholar
  23. 23.
    Marder SR, Chenoweth DE, Goldstein IM, and Perez HD. Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides c5a and c5a des arg. Jlmmunol 1985; 134: 3325–3331.Google Scholar
  24. 24.
    Kay AB, Pepper DS, and Ewart MR. Generation of chemotactic activity for leukocytes by the action of thrombin of human fibrinogen. Nature (Lond) 1973; 243: 56, 57.Google Scholar
  25. 25.
    Bar-Shavit R, Kahn A, Fenton JW, and Wilner GD. Chemotactic response of monocytes to thrombin. J Cell Biol 1983; 96: 282–285.CrossRefGoogle Scholar
  26. 26.
    Postlethwaite AE, Sayer JM, and Kang AH. Collagen-and collagen peptide-induced chemotaxis of human blood monocytes. JExp Med 1976; 143: 1299–1307.CrossRefGoogle Scholar
  27. 27.
    Senior RM, Griffin GL, and Mecham RP. Chemotactic activity of elastin-derived peptides. J Clin Invest 1980; 66: 859–862.CrossRefGoogle Scholar
  28. 28.
    Norris DA, Clark RAF, Swigart LM, Huff JC, Weston WL, and Howell SE. Fibronectin fragment(s) are chemotactic for human peripheral blood monocytes. J Immunol 1982; 129: 1612–1618.Google Scholar
  29. 29.
    Greisler HP, Dennis JW, Endean ED, Ellinger J, Friesel R, and Burgess WH. Macrophage/biomaterial interaction: the stimulation of endothelialization. J Vasc Surg 1989; 9: 588–593.Google Scholar
  30. 30.
    Greisler HP. Small diameter vascular prostheses:macrophage-biomaterial interactions with bioresorbable vascular prostheses. Trans ASAIO 1988; 34: 1051–1059.Google Scholar
  31. 31.
    Greisler HP. Pharmacology of the arterial wall, in Atherosclerosis: Human Pathology dnd Experimental Methods and Models 1989; (White RA, ed), CRC, Boca Raton, FL, pp 111–150.Google Scholar
  32. 32.
    Clowes AW, Gown AM, Hanson SR, and Reidy MA. Mechanisms of arterial graft failure: I. Role of cellular proliferation in early healing of PTFE prostheses. Am JPath 1985; 118: 43–54.Google Scholar
  33. 33.
    Reidy MA, Clowes AW, and Schwartz SM. Endothelial regeneration V. Inhibition of endothelial regrowth in arteries of rat and rabbit. Lab Invest 1983; 49: 569–575.Google Scholar
  34. 34.
    Reidy MA. Biology of disease: a reassessment of endothelial injury and arterial lesion formation. Lab Invest 1985; 53: 513–520.Google Scholar
  35. 35.
    Clowes AW, Kirieman TR, and Reidy MA. Mechanisms of arterial graft healing. Am J Path 1986; 123: 220–230.Google Scholar
  36. 36.
    Davies PF. Vascular cell interactions with special reference to the pathogenesis of atherosclerosis. Lab Invest 1986; 55: 5–24.Google Scholar
  37. 37.
    Bowen-Pope DF and Ross R. Platelet-derived growth factor. II. Specific binding to cultured cells. JBiol Chem 1982; 257: 5161–5168.Google Scholar
  38. 38.
    Grotendorst GR, Chang T, Seppa HEJ, Kleinman HK, and Martin GR. Platelet-derived growth factor is a chemoattractant for vascular smooth muscle cells. JCell Physiol 1982; 113: 261–266.CrossRefGoogle Scholar
  39. 39.
    Heldin C-H and Ronnstrand L. Characterization of the receptor for platelet-derived growth factor on human fibroblasts: demonstration of an intimate relationship with a 185,000-dalton substrate for the platelet-derived growth factor-stimulated kinase. JBiol Chem 1983; 258: 10,054–10,061.Google Scholar
  40. 40.
    Habenicht AJR, Glomset JA, King WC, Nist C, Mitchell CD, and Ross R. Early changes in phosphatidylinositol and arachidonic acid metabolism in quiescent swiss 3t3 cells stimulated to divide by platelet-derived growth factor. J Biol Chem 1981; 256: 12, 329–12, 335.Google Scholar
  41. 41.
    Hahenicht AJR, Goerig M, Grulich J, Rothe D, Gronwald R, Luth U, Human platelet-derived growth factor stimulates prostaglandin synthesis by activation and by rapid de novo synthesis of cyclooxygenase.JClinInvest 1985; 75: 1381–1387.Google Scholar
  42. 42.
    Chait A, Ross R, Albers J, and Bierman E. Platelet-derived growth factor stimulates activity of low density lipoprotein receptors. Proc Natl Acad Sci USA 1980; 77: 4084–4088.CrossRefGoogle Scholar
  43. 43.
    Berk BC, Alexander RW, Brock TA, Gimbrone MA Jr and Webb RC. Vasoconstriction: a new activity for platelet-derived growth factor. Science 1986; 932: 87–90.CrossRefGoogle Scholar
  44. 44.
    Gospodarowicz D, Mescher AL, and Birdwell CR. Stimulation of corneal endothelial cell proliferation in vitro by fibroblast and epidermal growth factors. Exp Eye Res 1977; 25: 75–89.CrossRefGoogle Scholar
  45. 45.
    Gospodarowicz D, Hirabayaski K, Giguere L, and Taliber J-P. Factors controlling the proliferative rate, final cell density, and life span of bovine vascular smooth muscle cells in culture. J Cell Biol 1981; 89: 568–578.CrossRefGoogle Scholar
  46. 46.
    Berk BC, Brock TA, Webb C, Taubman MB, Atkinson WJ, Gimbrone MA Jr, et al. Epidermal growth factor, a vascular smooth muscle mitogen, induces rat aortic contraction. J Clin Invest 1985; 75: 1083–1086.CrossRefGoogle Scholar
  47. 47.
    Petsikas D, Cziperle DJ, Lam TM, Murchan P, Henderson SC, and Greisler HP. Dacron-induced TGF-ß release from macrophages: effects on graft healing. Surg For 1991; 42: 326–328.Google Scholar
  48. 48.
    Anzano MA, Roberts AB, and Sporn MB. Anchorage-independent growth of primary rat embryo cells is induced by platelet-derived growth factor and inhibited by type-beta transforming growth factor. J Cell Physiol 1986; 126: 317–318.CrossRefGoogle Scholar
  49. 49.
    Leibovich SJ and Ross R. The role of the macrophage in wound repair. Am J Pathol 1975; 78: 71–100.Google Scholar
  50. 50.
    Shimokado K, Raines EW, Madtes DK, Burrett TB, Benditt EP, and Ross R. A significant part of macrophage-derived growth factor consists of at least two forms of PDGF. Cell1985; 43: 277–286.Google Scholar
  51. 51.
    Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, and Gimbrone MA Jr. Interleukin I- (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. JExp Med 1984; 160: 618–623.CrossRefGoogle Scholar
  52. 52.
    Reidy MA, Fingerle J, and Lindner V: Factors controlling the development of arterial lesions after injury. Circulation 1992; 86(Suppl): I1I43—III46Google Scholar
  53. 53.
    Greisler HP, Ellinger J, Schwarcz TH, Golan J, Raymond RM, and Kim DU. Arterial regeneration over polydioxanone prostheses in the rabbit. Arch Surg 1987; 199: 715–721.CrossRefGoogle Scholar
  54. 54.
    Greisler HP. Arterial regeneration over resorbable prostheses. Arch Surg 1982; 117: 1425–1431.CrossRefGoogle Scholar
  55. 55.
    Greisler HP, Kim DU, Price JB, and Voorhees AB. Arterial regenerative activity after prosthetic implantation. Arch Surg 1985; 120: 315–323.CrossRefGoogle Scholar
  56. 56.
    Greisler HP and Kim DU. Aspects of biodegradable vascular grafts, in Vascular Graft Update: Safety and Performance 1986; (Kambic HE, Kantrowitz A, and Sung P), ASTM, pp 197–218.Google Scholar
  57. 57.
    Greisler HP, Kim DU, Dennis JW, Klosak JJ, Widerborg KA, Endean ED, et al. Compound polyglactin 910/polypropylene small vessel prostheses. J Vasc Surg 1987; 5: 572–583.Google Scholar
  58. 58.
    Greisler HP and Kim DU. Vascular grafting in the management of thrombotic disorders. Sem Thromb Haemostasis 1989; 15: 206–214.CrossRefGoogle Scholar
  59. 59.
    Greisler HP, Endean ED, Klosak JJ, Ellinger J, Dennis JW, Buttle K, et al. Polyglactin 910/ polydioxanone bicompent totally resorbable vascular prostheses. J Vasc Surg 1988; 7: 697–705.Google Scholar
  60. 60.
    Gajdusek CM, DiCorleto PE, Ross R, and Schwartz SM. An endothelial cell derived growth factor. J Cell Biol 1980; 85: 467–472.CrossRefGoogle Scholar
  61. 61.
    DiCorleto PE, Gajdusek CM, Schwartz SM, and Ross R. Biochemical properties of the endothelium-derived growth factor: comparison to other growth factors. JCell Physiol 1983; 114: 339–345.Google Scholar
  62. 62.
    DiCorleto PE and Bowen-Pope DF. Cultured endothelial cells produce a platelet-derived growth factor-like protein. Proc Natl Acad Sci USA 1983; 80: 1919–1923.CrossRefGoogle Scholar
  63. 63.
    Fox PL and DiCorleto PE. Acetylated low density lipoprotein suppresses production of platelet-derived growth factor by cultured endothelial cells. J Cell Biol 1985; 101: 107a.Google Scholar
  64. 64.
    Fox PL and DiCorleto PE. Modified low density lipoproteins suppress production of a platelet-derived growth factor-like protein by cultured endothelial cells. Proc Natl Acad Sci USA 1986; 83: 4774–4778.CrossRefGoogle Scholar
  65. 65.
    Harlan JM, Bowen-Pope D, Thompson PJ, and Ross R. Alpha-thrombin induces secretion of platelet-derived growth factor-like molecules from cultured human endothelial cells. Thromb Haemostasis 1985; 54: 168.Google Scholar
  66. 66.
    Gajdusek C, Carbon S, Ross R, Nawroth P, and Stern D. Activation of coagulation releases endothelial cell mitogens. J Cell Biol 1986; 102: 419–428.CrossRefGoogle Scholar
  67. 67.
    Greisler HP, Schwarcz TH, Ellinger J, and Kim DU. Dacron inhibition of arterial regenerative activity. J Vasc Surg 1986; 3: 747–756.Google Scholar
  68. 68.
    Greisler HP, Dennis JW, Endean ED, and Kim DU. Derivation of neointima in vascular grafts. Circulation 1988; 78 (suppl I): 16–112.Google Scholar
  69. 69.
    Hasson JE, MegermanJ, and Abott WM. Increased compliance near vascular anastomoses. J Vasc Surg 1985; 2: 419–423.Google Scholar
  70. 70.
    Sumpio BE, Banes AJ, Levin LG, and Johnson G Jr. Mechanical stress stimulates aortic endothelial cells to proliferate. J Vasc Surg 1987; 6: 252–256.Google Scholar
  71. 71.
    Sumpio BE, Banes AJ, and Buckley M. Alterations in aortic endothelial cell morphology and cytosketetal protein synthesis during cyclic tensional deformation. J Vasc Surg 1988; 7: 130–138.Google Scholar
  72. 72.
    Sumpio BE, Banes AJ, and Johnson G. Enhanced collagen production by smooth muscle cells during mechanical stretching. Arch Surg 1988; 123: 1233–1236.CrossRefGoogle Scholar
  73. 73.
    Iba T, Mills I, and Sumpio BE. Intracellular cyclic AMP levels in endothelial cells subjected to cyclic strain in vitro. Jsurgres 1992; 52: 625–630.Google Scholar
  74. 74.
    Endean ED, Kim DU, Ellinger J, Henderson S, and Greisler HP. Effects of polypropylene’s mechanical properties on histological and functional reactions to polyglactin 910/polypropylene vascular prostheses. Surg For 1987; 38: 323–325.Google Scholar
  75. 75.
    Zenni GC, Gray JL, Appelgren LEO, Kim DU, Berceli S, Liguish J, Modulation of myofibroblast proliferation by vascular prosthesis biomechanics. ASAIO J 1993; M496 — M500.Google Scholar
  76. 76.
    Cambria RP and Abbott WM. Translocated autogenous vein grafts, in Vascular Surgery 1989; (Rutherford RB, ed), Saunders, Philadelphia, pp 425–434.Google Scholar
  77. 77.
    Greisler HP, Pham SM, Endean ED, Durham SJ, Kim DU, Mehta SM, Relationship between changes in biomechanical properties and cellular ingrowth in resorbable vascular prostheses. Am Soc ArtifInter Organs (ASAIO)Abs 1987; 16: 25.Google Scholar
  78. 78.
    Pham S, Durham S, Johnson R, Showalter D, Endean ED, Vorp DA, et al. Compliance changes in bioresorbable vascular prostheses following implantation. Surg For 1988; 39: 440–443.Google Scholar
  79. 79.
    Greisler HP. Macrophage activation in bioresorbable vascular grafts, in Vascular Endothelium: Physiological Basis of Clinical Problems. 1991; (Catravas JD, Callow AD, Gillis CN, and Ryan U), Plenum, New York, pp 253, 254.Google Scholar
  80. 80.
    Cabusao EB, Lam TM, Ellinger J, and Greisler HP. Kinetics of collagen deposition within bioresorbable and nonresorbable vascular prostheses. Trans Am Soc Artif Int Organs (ASAIO) 1991; 37: M472 — M475.Google Scholar
  81. 81.
    Tattersall CW, Klosak JJ, Cabusao EA, Kim DU, and Greisler HP. Partially bioresorbable arterial prostheses in the dog. Surgery 1991; 110: 645–655.Google Scholar
  82. 82.
    Greisler HP, Klosak JJ, Endean ED, McGurrin JF, and Kim DU. Effects ofhypercholesterolemia on healing of vascular grafts. JInvest Surg 1991; 4: 299–312.CrossRefGoogle Scholar
  83. 83.
    Lommen E, Gogolewski S, Pennings AJ, Wilde-burr CRH, and Nieuwenhuis P. Development of a neo-artery induced by a biodegradable polymeric vascular prosthesis. Trans Am Soc Artif Intern Organs 1983; 29: 255–259.Google Scholar
  84. 84.
    van der Lei B. Blaau EH, Dijk F, Bartels H, Wildevuur CRH, Nieuwenhusi P, Micro-porous compliant biodegradable graft materials: a new concept for microvascular surgery, in Recent Advances in Vascular Grafting 1984; (Skotnicki SH, Buskens FGM, and Reinaerts HHM), Nijmegan, The Netherlands, pp 19–23.Google Scholar
  85. 85.
    van der Lei B, Darius H, Schror K, Molenaar I, Nieuwenhuis P, and Wildevuur CRH. Improved neo-endothelialization of small caliber vascular grafts. ESAO Proc 1984; 2 (suppl 1): 332–334.Google Scholar
  86. 86.
    van der Lei B, Wildevuur CRH, Nieuwenhuis P, Blaauw EH, Dijk F, Hulstaert CE, et al. Regeneration of the arterial wall in microporous, compliant, biodegradable vascular grafts after implantation into the rat abdominal aorta. Cell Tissue Res 1985; 242: 569–578.CrossRefGoogle Scholar
  87. 87.
    van der Lei B, Darius H, Schror K, Nieuwenhuis P, Molenaar I, and Wildevuur CRH. Arterial wall regeneration in small-caliber vascular grafts in rats. J Thorac Cardiovasc Surg 1985; 90 (3): 378–386.Google Scholar
  88. 88.
    van der Lei B, Bartels HL, Nieuwenhuis P, and Wildevuur CRH. Microporous, compliant, biodegradable vascular grafts for the regeneration of the arterial wall in rat abdominal aorta. Surgery 1985; 98: 955–963.Google Scholar
  89. 89.
    van der Lei B, Wildevuur CRH, and Nieuwenhuis P. Compliance and biodegradation of vascular grafts stimulate the regeneration of elastic laminae in neoarterial tissue: an experimental study in rats. Surgery 1986; 99 (1): 45–52.Google Scholar
  90. 90.
    van der Lei B, Wildevuur CRH, Dijk F, Blaauw EH, Molenaar I, and Nieuwenhuis P. Sequential studies of arterial wall regeneration in micro-porous, compliant, biodegradable small-caliber vascular grafts in rats. J Thorac Cardiovasc Surg 1987; 93: 695–707.Google Scholar
  91. 91.
    van der Lei B, Nieuwenhuis P, Molenaar I, and Wildevuur CRH. Long-term biologic fate of neoarteries regenerated in microporous, compliant, biodegradable, small-caliber vascular grafts in rats. Surgery 1987; 101: 459—.467.Google Scholar
  92. 92.
    Yue X, van der Lei B, Schakenraad JM, van Oene GH, Juit JH, Feijen J, et al. Smooth muscle cell seeding in biodegradable grafts in rats: a new method to enhance the process of arterial wall regeneration. Surgery 1988; 103: 206–212.Google Scholar
  93. 93.
    Galletti PM, Ip TK, Chiu T-H, Nyilas E, Trudell LA, and Sasken H. Extending the functional life of bioresorbable yarns for vascular grafts. Trans Am Soc Artif Intern Organs 1984; 30: 399, 400.Google Scholar
  94. 94.
    Galletti PM, Trudell LA, Chiu TH, Sasken H, Richardson PD, Parhizgar A, et al. Coated bioresorbable mesh as vascular graft material. Trans Am Soc Artif Intern Organs 1985; 31: 257–263.Google Scholar
  95. 95.
    Galletti PM, Aebischer P, Sasken HF, Goddard MB, and Chiu T-H. Experience with fully bioresorbable aortic grafts in the dog. Surgery 1988; 103: 231–141.Google Scholar
  96. 96.
    Greisler HP, Ellinger J, Henderson SC, Shaheen AM, Burgess WH, and Lam TM. The effects of an atherogenic diet on macrophage/biomaterial interactions. J Vasc Surg 1991; 14: 10–23.CrossRefGoogle Scholar
  97. 97.
    Greisler HP, Dennis JW, Endean ED, Ellinger J, Friesel R, and Burgess WH. Macrophage/ biomaterial interactions-the stimulation of endothelialization. J Vasc Surg 1989; 9: 588–593.Google Scholar
  98. 98.
    Greisler HP. The role of the macrophages in intimai hyperplasia. J Vasc Surg 1989; 10: 566–568.CrossRefGoogle Scholar
  99. 99.
    Greisler HP, Cziperle DJ, Kim DU, Garfield JD, Petsikas D, Murchan PM, et al. Enhanced endothelialization of expanded polytetrafluoroethylene grafts by fibroblast growth factor type 1 pretreatment. Surgery 1992; 112: 244–255.Google Scholar
  100. 100.
    Gray JL, Kang SS, Zenni GC, Kim DU, Kim PI, Burgess WH, et al. FGF-1 affixation stimulates ePTFE endothelialization without intimai hyperplasia. J Surg Res 1994; 57: 596–612.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Howard P. Greisler

There are no affiliations available

Personalised recommendations